A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)

J. Randolph Hecht(UCLA Jonsson Comprehensive Cancer Center), Christian Jacques(Bibliothèque et Archives nationales du Québec), M. Borner(Virginia Cancer Institute), E. Jaeger(Krankenhaus Nordwest), G. Bodoky(Unified Szent István and Szent László Hospital), Tanja Trarbach(Virginia Cancer Institute), John D. Hainsworth(Sarah Cannon), Dirk Laurent(Menarini Group (Germany)), R.A. Wolff(Virginia Cancer Institute), Kenneth O. Lloyd(Memorial Sloan Kettering Cancer Center)

Journal of Clinical Oncology

June 1, 2005

10.1200/jco.2005.23.16_suppl.lba3

Cited by 201

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

|The Lancet Oncology|2015|954

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

|Journal of Clinical Oncology|2008|852

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

|The Lancet Oncology|2013|838